Meeting Banner
Abstract #0474

First clinical experience using fluorine-19 MRI to track immunotherapeutic dendritic cells in colorectal cancer patients

Eric T Ahrens 1 , Anthony Balducci 2 , Brooke Helfer 2 , Amy Wesa 2 , Charles O'Hanlon 2 , Claudiu Schirda 3 , David Bartlett 4 , and Pawel Kalinski 4

1 Radiology, University of California at San Diego, La Jolla, CA, United States, 2 Celsense, Inc., Pittsburgh, PA, United States, 3 Radiology, University of Pittsburgh, Pittsburgh, PA, United States, 4 Surgical Oncology, University of Pittsburgh, Pittsburgh, PA, United States

Cell therapies, such as those employing immune or stem cells, can benefit from non-invasive imaging to visualize cells following transfer into the patient. We described the first clinical use of a fluorine-19 MRI tracer agent designed for MRI cell tracking. We labeled autologous immunotherapeutic dendritic cells (DCs) with a perfluorocarbon (PFC) tracer agent ex vivo. Labeled DCs were inoculated into colorectal cancer patients. Cells were detected using a 3T scanner using 19F MRI/MRS. Clinical 19F-based cell tracking is feasible and provides unambiguous information about the cell location, with no background signal, and can be used to quantify cells in situ.

This abstract and the presentation materials are available to members only; a login is required.

Join Here